Cargando…

Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients

BACKGROUND: The aim of this study was to investigate the expression level of circulating microRNA-31(miRNA-31) in lung cancer patients and its clinical significance. MATERIAL/METHODS: Real-time fluorescent quantitative PCR was utilized to detect the circulating miRNA-31 expression levels in 300 lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Hai-Jun, Ma, Ji-Yong, Wang, Li, Gu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362487/
https://www.ncbi.nlm.nih.gov/pubmed/25765717
http://dx.doi.org/10.12659/MSM.893213
_version_ 1782361820799959040
author Yan, Hai-Jun
Ma, Ji-Yong
Wang, Li
Gu, Wei
author_facet Yan, Hai-Jun
Ma, Ji-Yong
Wang, Li
Gu, Wei
author_sort Yan, Hai-Jun
collection PubMed
description BACKGROUND: The aim of this study was to investigate the expression level of circulating microRNA-31(miRNA-31) in lung cancer patients and its clinical significance. MATERIAL/METHODS: Real-time fluorescent quantitative PCR was utilized to detect the circulating miRNA-31 expression levels in 300 lung cancer patients and 300 health control subjects. The ROC curve was drawn to evaluate the diagnostic value of the circulating miRNA-31 expression levels in lung cancer. The 300 lung cancer patients were divided into a miRNA-31 low-expression group and a miRNA-31 high-expression group. A survival curve was drawn according to the Kaplan-Meier method to evaluate the prognostic value of the circulating microRNA-31 expression levels for lung cancer. RESULTS: The circulating miRNA-31 expression levels in the lung cancer patients (l.88±0. 67) increased significantly (P<0.001) compared to the healthy controls (0.58±0. 44). The area under the ROC curve drawn according to the circulating miRNA-31 expression levels was 0.785 (95% CI=0.486–0.763). When the critical value was 1.27, the sensitivity and specificity for lung cancer diagnosis according to the circulating miRNA-31 expression levels were 0.769 and 0.745, respectively. The difference in the survival curve between the miRNA-31 low-expression group (123 cases) and high-expression group (177 cases) was statistically significant (P=0.004). Median survival period of the low-expression group (38.44 months) was longer than that of the high-expression group (25.23 months). CONCLUSIONS: miRNA-31 may be a molecular marker for the diagnostic and prognostic evaluation of primary lung cancer.
format Online
Article
Text
id pubmed-4362487
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-43624872015-03-25 Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients Yan, Hai-Jun Ma, Ji-Yong Wang, Li Gu, Wei Med Sci Monit Clinical Research BACKGROUND: The aim of this study was to investigate the expression level of circulating microRNA-31(miRNA-31) in lung cancer patients and its clinical significance. MATERIAL/METHODS: Real-time fluorescent quantitative PCR was utilized to detect the circulating miRNA-31 expression levels in 300 lung cancer patients and 300 health control subjects. The ROC curve was drawn to evaluate the diagnostic value of the circulating miRNA-31 expression levels in lung cancer. The 300 lung cancer patients were divided into a miRNA-31 low-expression group and a miRNA-31 high-expression group. A survival curve was drawn according to the Kaplan-Meier method to evaluate the prognostic value of the circulating microRNA-31 expression levels for lung cancer. RESULTS: The circulating miRNA-31 expression levels in the lung cancer patients (l.88±0. 67) increased significantly (P<0.001) compared to the healthy controls (0.58±0. 44). The area under the ROC curve drawn according to the circulating miRNA-31 expression levels was 0.785 (95% CI=0.486–0.763). When the critical value was 1.27, the sensitivity and specificity for lung cancer diagnosis according to the circulating miRNA-31 expression levels were 0.769 and 0.745, respectively. The difference in the survival curve between the miRNA-31 low-expression group (123 cases) and high-expression group (177 cases) was statistically significant (P=0.004). Median survival period of the low-expression group (38.44 months) was longer than that of the high-expression group (25.23 months). CONCLUSIONS: miRNA-31 may be a molecular marker for the diagnostic and prognostic evaluation of primary lung cancer. International Scientific Literature, Inc. 2015-03-09 /pmc/articles/PMC4362487/ /pubmed/25765717 http://dx.doi.org/10.12659/MSM.893213 Text en © Med Sci Monit, 2015 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
spellingShingle Clinical Research
Yan, Hai-Jun
Ma, Ji-Yong
Wang, Li
Gu, Wei
Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients
title Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients
title_full Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients
title_fullStr Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients
title_full_unstemmed Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients
title_short Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients
title_sort expression and significance of circulating microrna-31 in lung cancer patients
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362487/
https://www.ncbi.nlm.nih.gov/pubmed/25765717
http://dx.doi.org/10.12659/MSM.893213
work_keys_str_mv AT yanhaijun expressionandsignificanceofcirculatingmicrorna31inlungcancerpatients
AT majiyong expressionandsignificanceofcirculatingmicrorna31inlungcancerpatients
AT wangli expressionandsignificanceofcirculatingmicrorna31inlungcancerpatients
AT guwei expressionandsignificanceofcirculatingmicrorna31inlungcancerpatients